CMPX COMPASS THERAPEUTICS INC

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.

Presentation details

Date: Tuesday, April 16

Time: 11 – 11:25 AM ET

Webcast Link:

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’  page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at .

Investor Contact

 

Media Contact

Anna Gifford, Communications Manager

 

617-500-8099



EN
10/04/2024

Underlying

CMPXCOMPASS THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS THERAPEUTICS INC

 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual ...

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024. Fireside Chat detailsDate: Monday, May 20Time: 11:30 AM ETWebcast Link: Vir...

May 14, 2024 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Reports 2024 First Quarter Financial Results and ...

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025.Completed enrollment...

May 13, 2024 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Receives FDA Fast Track Designation for the Inves...

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study Top-line data readout for COMPANION-002, the Company’s randomized Phase 2/3 BTC U.S. study, is expected by the end of 2024 BOSTON, April 25, 2024 (GLO...

April 25, 2024 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Stud...

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker.  CTX-8371 is a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1.Compass advanced CTX-8371 to the clinic following pre-clinical observations of superior activity when compared with approved checkpoint ...

April 16, 2024 1 EN
 PRESS RELEASE
Free
CMPX COMPASS THERAPE...

Compass Therapeutics Announces Poster Presentations at the Cholangioca...

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19,...

April 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch